전사체학 진단 시장 : 전략적 인사이트와 예측(2026-2035년)

The Transcriptomics Diagnostics Market is estimated to grow to USD 13.89 billion in 2035 at a CAGR of 11.5% from USD 5.22 billion in 2026.

Transcriptomics diagnostics focuses on analyzing RNA expression profiles to understand disease mechanisms, identify biomarkers, support early diagnosis, and guide personalized treatment decisions. Unlike genomic testing, which identifies static DNA alterations, transcriptomics provides real-time insights into gene activity and cellular function. Advances in RNA sequencing (RNA-Seq), microarrays, quantitative PCR (qPCR), single-cell transcriptomics, artificial intelligence (AI), and cloud-based bioinformatics are enabling more comprehensive disease characterization and improving clinical decision-making. Growing integration of transcriptomic data into precision medicine programs is accelerating adoption across hospitals, diagnostic laboratories, research institutes, and pharmaceutical companies.

Market Drivers

Growing Adoption of Precision Medicine

Healthcare providers increasingly rely on molecular profiling to personalize treatment strategies. Transcriptomics diagnostics enables clinicians to understand gene expression changes associated with disease progression, therapeutic response, and drug resistance, supporting individualized patient management.

Rising Demand for RNA-Based Biomarkers

RNA biomarkers are becoming increasingly important for disease diagnosis, prognosis, and therapy monitoring. Transcriptomic profiling enables earlier disease detection while improving patient stratification across oncology, neurology, immunology, and infectious diseases.

Technological Advancements in Sequencing

Continuous improvements in next-generation sequencing, quantitative PCR, single-cell RNA sequencing, and bioinformatics platforms have significantly enhanced the speed, accuracy, and affordability of transcriptomic analysis. These innovations are expanding both research and clinical applications.

Increasing Investment in Genomic Research

Governments, healthcare organizations, pharmaceutical companies, and academic institutions continue investing heavily in genomics and transcriptomics research to accelerate biomarker discovery, companion diagnostics, and drug development.

Market Restraints

High Cost of Advanced Molecular Diagnostics

Comprehensive transcriptomic analysis requires sophisticated sequencing instruments, laboratory infrastructure, computational resources, and specialized personnel, limiting adoption in smaller healthcare facilities.

Complex Data Analysis

Transcriptomic datasets generate enormous volumes of information that require advanced bioinformatics, AI algorithms, and experienced molecular pathologists for accurate clinical interpretation.

Regulatory and Clinical Validation Requirements

Clinical implementation requires extensive validation, quality assurance, and regulatory approval before transcriptomic assays can be routinely incorporated into diagnostic workflows.

Market and Technology Insights

The global transcriptomics diagnostics market can be segmented by product & service, technology, application, end user, and geography.

By product & service, the market includes:

• Instruments
• Reagents & Consumables
• Software & Bioinformatics Solutions
• Diagnostic Testing Services

Reagents and consumables account for a substantial market share because of continuous demand across sequencing workflows, while bioinformatics software is experiencing rapid growth due to increasing adoption of AI-assisted analytics.

By technology, the market comprises:

• RNA Sequencing (RNA-Seq)
• Quantitative PCR (qPCR)
• Microarrays
• Single-Cell RNA Sequencing
• Digital PCR
• Other Transcriptomic Technologies

RNA sequencing represents the leading technology because of its ability to comprehensively analyze gene expression, while single-cell RNA sequencing is expanding rapidly through its ability to characterize cellular heterogeneity.

By application, the market includes:

• Oncology Diagnostics
• Infectious Disease Diagnostics
• Neurological Disorders
• Genetic Disorders
• Precision Medicine
• Companion Diagnostics

Oncology remains the largest application owing to increasing use of RNA signatures for tumor classification, biomarker identification, therapy selection, and disease monitoring.

By end user, the market serves:

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)

Hospitals and diagnostic laboratories continue expanding transcriptomic testing capabilities as precision diagnostics become more widely adopted.

Market Trends

The transcriptomics diagnostics market continues evolving through technological innovation.

Key trends include:

• Increasing adoption of single-cell transcriptomics.
• Expansion of AI-powered bioinformatics.
• Growing integration of multi-omics diagnostics.
• Rising development of companion diagnostics.
• Expansion of cloud-based genomic analysis.
• Increasing automation of laboratory workflows.
• Growing utilization of liquid biopsy and RNA biomarkers.

Regional Insights

North America remains the largest market because of strong precision medicine initiatives, advanced molecular diagnostic infrastructure, substantial genomics research funding, and widespread adoption of RNA sequencing technologies.

Europe continues experiencing steady growth through expanding genomic medicine programs, increasing implementation of molecular diagnostics, and growing collaboration between research institutions and healthcare providers.

Asia-Pacific is expected to register the fastest growth owing to expanding healthcare infrastructure, increasing biotechnology investment, improving genomic research capabilities, and rising demand for personalized medicine. China, Japan, South Korea, India, and Australia are driving regional expansion.

Latin America and the Middle East & Africa are gradually strengthening molecular diagnostic capabilities through healthcare modernization, government investment, and international research collaborations.

Competitive Landscape

The market is characterized by continuous innovation in sequencing platforms, molecular diagnostics, bioinformatics, and AI-enabled analytical solutions.

Major companies include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, Roche Diagnostics, Bio-Rad Laboratories, Standard BioTools (formerly Fluidigm), Oxford Nanopore Technologies, Pacific Biosciences (PacBio), 10x Genomics, NanoString Technologies, and BGI Genomics. Companies continue investing in RNA sequencing technologies, AI-powered interpretation platforms, integrated bioinformatics solutions, and strategic collaborations to strengthen their competitive positions.

Future Outlook

The future of the transcriptomics diagnostics market will be driven by broader implementation of precision medicine, increasing use of RNA biomarkers, continued advances in sequencing technologies, and growing integration of transcriptomics with multi-omics platforms. Improvements in automation, artificial intelligence, cloud computing, and single-cell analysis are expected to make transcriptomic diagnostics increasingly accessible for routine clinical applications while accelerating biomarker discovery and personalized treatment development.

Conclusion

The Global Transcriptomics Diagnostics Market is expected to witness robust growth through 2035, supported by increasing demand for precision diagnostics, expanding applications of RNA-based biomarkers, and continuous innovation in sequencing technologies. Although challenges related to implementation costs, bioinformatics complexity, and regulatory requirements remain, advances in transcriptomic technologies are expected to create significant opportunities for diagnostic manufacturers, biotechnology companies, healthcare providers, researchers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global transcriptomics diagnostics market.
• Detailed evaluation of technologies, applications, and emerging innovations.
• Analysis of competitive strategies, technological developments, and commercialization opportunities.
• Insights into precision medicine, RNA biomarkers, AI-enabled diagnostics, and companion diagnostics.
• Valuable resource for diagnostic companies, biotechnology firms, healthcare providers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive benchmarking, precision medicine strategy, biomarker discovery, companion diagnostic development, commercialization planning, partnership evaluation, investment analysis, regulatory planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global transcriptomics diagnostics market by Product & Service, Technology, Application, End User, and Geography
• Evaluation of market dynamics, technology innovation, competitive landscape, regulatory environment, and future growth opportunities
• Assessment of RNA sequencing, quantitative PCR, microarrays, single-cell RNA sequencing, oncology diagnostics, infectious disease diagnostics, precision medicine, companion diagnostics, AI-enabled bioinformatics, and commercialization strategies
• Analysis of instruments, reagents & consumables, software & bioinformatics solutions, diagnostic services, hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, academic research institutes, and emerging transcriptomics diagnostic technologies through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Transcriptomics Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Gene Expression Diagnostics Ecosystem Overview
• 3.8 Molecular Diagnostic Workflow Overview
• 3.9 Testing Volume Analysis
• 3.10 User Adoption Analysis
• 3.11 Clinical Utility of Transcriptomics Diagnostics
• 3.12 Precision Medicine and Companion Diagnostics Landscape

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in Transcriptomics Diagnostics
• 6.2 Product Innovation Analysis
• 6.3 RNA Sequencing Advancements
• 6.4 Spatial Transcriptomics Innovations
• 6.5 Multiplex Gene Expression Technologies
• 6.6 Clinical Trial Analysis
• 6.7 Pipeline Analysis
• 6.8 AI Integration in Transcriptomic Data Interpretation
• 6.9 Digital Health and Bioinformatics Integration
• 6.10 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Transcriptomics Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Diagnostic Technology
• 8.3 Analysis by Biomarker Type
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by Testing Setting
• 8.7 Analysis by End User

9. Transcriptomics Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product & Service
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software & Bioinformatics Solutions
  • 9.1.4 Diagnostic Testing Services
• 9.2 By Technology
  • 9.2.1 RNA Sequencing (RNA-Seq)
  • 9.2.2 Reverse Transcription PCR (RT-PCR)
  • 9.2.3 Microarrays
  • 9.2.4 Digital PCR
  • 9.2.5 Spatial Transcriptomics
• 9.3 By Sample Type
  • 9.3.1 Tissue Samples
  • 9.3.2 Blood Samples
  • 9.3.3 Other Biological Samples
• 9.4 By Application
  • 9.4.1 Oncology
  • 9.4.2 Infectious Diseases
  • 9.4.3 Rare Genetic Disorders
  • 9.4.4 Neurological Disorders
  • 9.4.5 Autoimmune Diseases
  • 9.4.6 Cardiovascular Diseases
  • 9.4.7 Other Applications
• 9.5 By End User
  • 9.5.1 Hospitals & Clinical Laboratories
  • 9.5.2 Reference Laboratories
  • 9.5.3 Academic & Research Institutes
  • 9.5.4 Pharmaceutical & Biotechnology Companies
  • 9.5.5 Other End Users

10. Transcriptomics Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Transcriptomics Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 China
• 11.8 Japan
• 11.9 South Korea
• 11.10 India
• 11.11 Australia
• 11.12 Brazil
• 11.13 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd
• 13.2 Illumina, Inc.
• 13.3 Thermo Fisher Scientific Inc.
• 13.4 QIAGEN N.V.
• 13.5 Agilent Technologies, Inc.
• 13.6 Bio-Rad Laboratories, Inc.
• 13.7 10x Genomics, Inc.
• 13.8 Standard BioTools Inc.
• 13.9 NanoString Technologies, Inc.
• 13.10 Oxford Nanopore Technologies plc
• 13.11 Pacific Biosciences of California, Inc.
• 13.12 Bruker Corporation
• 13.13 Merck KGaA
• 13.14 Takara Bio Inc.
• 13.15 Parse Biosciences, Inc.

14. Transcriptomics Diagnostics Market Commercial Forecast Analysis

• 14.1 Forecast by Instruments
• 14.2 Forecast by Reagents & Consumables
• 14.3 Forecast by Software & Bioinformatics Solutions
• 14.4 Forecast by Diagnostic Testing Services
• 14.5 Forecast by Oncology Diagnostics
• 14.6 Forecast by Infectious Disease Diagnostics
• 14.7 Forecast by Rare Disease Diagnostics
• 14.8 Forecast by Spatial Transcriptomics Diagnostics

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends